CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Activated T lymphocytebiological
Likely dose
Activated T lymphocyte 200 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00965718
NCT00965718Phase 2Completed
CompareCT.gov

Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte ("Immuncell-LC") Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer

GC Cell Corporation·interventional·Posted Aug 26, 2009·Updated Jul 19, 2023

In Brief

A Phase 2 clinical trial evaluating Activated T lymphocyte for Pancreatic Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte ("Immuncell-LC") cell therapy in Gemcitabine refractory advanced pancreatic cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesSouth Korea
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 26, 2009
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago

Interventions

Activated T lymphocytebiological

Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.